BusinessEsperion Announces Initiation of Global Cardiovascular Outcomes Trial for Bempedoic AcidBy Nasdaq OMXJan 9, 2017, 1:05 PM UTC
BusinessEsperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic AcidBy Nasdaq OMXJan 8, 2017, 9:00 PM UTC
BusinessEsperion to Present at the 35th Annual J.P. Morgan Healthcare ConferenceBy Nasdaq OMXJan 4, 2017, 10:00 PM UTC
BusinessSECURITIES NOTICE: Rosen Law Firm Reminds Esperion Therapeutics, Inc. Investors of Important March 14, 2016 Deadline in Class Action – ESPRBy Nasdaq OMXMar 4, 2016, 8:30 PM UTC
BusinessEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Esperion Therapeutics, Inc. -- ESPRBy Nasdaq OMXFeb 11, 2016, 9:40 PM UTC
